Cellectis (NASDAQ:CLLS) Given "Sell (D-)" Rating at Weiss Ratings

Key Points

• Cellectis (NASDAQ: CLLS) has been reissued a "Sell (D-)" rating by Weiss Ratings, indicating a negative outlook for the stock.
• Despite the negative rating from Weiss, some analysts have provided more positive assessments, with Barclays raising their target price to $8.00 and rating the stock as "overweight."
• As of the latest report, Cellectis reported a negative net margin of 100.69%, but had revenue of $18.19 million for the quarter, surpassing expectations.

Cellectis (NASDAQ:CLLS - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Friday,Weiss Ratings reports.

CLLS has been the subject of several other reports. Wall Street Zen raised shares of Cellectis to a "hold" rating in a report on Saturday, September 20th. Barclays raised their target price on Cellectis from $4.00 to $8.00 and gave the stock an "overweight" rating in a research note on Friday, October 17th. Finally, Wells Fargo & Company reiterated a "positive" rating and issued a $4.00 target price on shares of Cellectis in a report on Monday. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $6.00.

Cellectis Stock Performance

CLLS traded up $0.01 during trading on Friday, hitting $3.48. The company's stock had a trading volume of 44,063 shares, compared to its average volume of 219,761. The business's 50 day simple moving average is $3.27 and its 200-day simple moving average is $2.26. The firm has a market cap of $192.88 million, a PE ratio of -4.24 and a beta of 3.10. Cellectis has a one year low of $1.10 and a one year high of $5.48. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.58.

Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.09). Cellectis had a negative net margin of 100.69% and a negative return on equity of 68.05%. The company had revenue of $18.19 million for the quarter, compared to the consensus estimate of $10.07 million. As a group, sell-side analysts predict that Cellectis will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. OLD Mission Capital LLC acquired a new stake in Cellectis during the 1st quarter worth about $31,000. Acadian Asset Management LLC increased its stake in shares of Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 26,461 shares during the period. Long Focus Capital Management LLC raised its stake in Cellectis by 2.2% during the 1st quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company's stock valued at $5,849,000 after purchasing an additional 100,000 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Cellectis by 228.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company's stock valued at $5,856,000 after purchasing an additional 3,284,409 shares in the last quarter. Institutional investors and hedge funds own 63.90% of the company's stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.